Delta‐9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief

References

• Wolfe F, Smythe HA, Yunus MB, Bennett RM, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–72
   PubMed Web of Science ®Google Scholar
• Sim J, Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Clin J Pain 2002;18:324–36
   PubMed Web of Science ®Google Scholar
• Guhring H, Schuster J, Hamza M, Ates M, et al. HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur J Pharmacol 2001;429:127–34
   PubMed Web of Science ®Google Scholar
• Rice AS, Farquhar-Smith WP, Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 2002;66:243–56
   PubMed Web of Science ®Google Scholar
• Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003;102:283–8
   PubMed Web of Science ®Google Scholar
• Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975;15:139–43
   PubMed Web of Science ®Google Scholar
• Neff GW, O’Brien CB, Reddy KR, Bergasa NV, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002;97:2117–9
   PubMed Web of Science ®Google Scholar
• Gonzales-Rosales F, Walsh D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (Dronabinol). J Pain Symptom Manage 1997;14:311–4
   Google Scholar
• Beal JE, Olson R, Lefkowitz L, Laubenstein L, et al. Long-term efficacy and safety of Dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997;14:7–14
   Google Scholar
• Tramer MR, Carroll D, Campbell FA, Reynolds DJ, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323: 16–21
   Google Scholar
• Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, et al. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003;105: 79–88
   Google Scholar
• Schmelz M, Michael K, Weidner C, Schmidt R, et al. Which nerve fibers mediate the axon reflex flare in human skin? Neuro-report 2000;11:645–8
   Google Scholar
• Schmelz M, Schmidt R, Ringkamp M, Handwerker HO, et al. Sensitization of insensitive branches of C nociceptors in human skin. J Physiol 1994;480:389–94
   Google Scholar
• Sauerstein K, Klede M, Hilliges M, Schmelz M. Electrically evoked neuropeptide release and neurogenic inflammation differ between rat and human skin. J Physiol 2000;529:803–10
   PubMed Web of Science ®Google Scholar
• Koltzenburg M, Lundberg LE, Torebjörk HE. Dynamic and static components of mechanical hyperalgesia in human hairy skin. Pain 1992;51:207–19
   Google Scholar
• Skopp G, Potsch L. An investigation of the stability of free and glucuronidated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in authentic urine samples. J Anal Toxicol 2004;28:35–40
   PubMed Web of Science ®Google Scholar
• Koppert W, Dern SK, Sittl R, Albrecht S, et al. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology 2001;95: 395–402
   Google Scholar
• Kjellby-Wendt G, Styf J, Carlsson SG. Early active rehabilitation after surgery for lumbar disc herniation: a prospective, randomized study of psychometric assessment in 50 patients. Acta Orthop Scand 2001;72: 518–24
   Google Scholar
• Thieme K, Gromnica-Ihle E, Flor H. Operant behavioral treatment of fibromyalgia: a controlled study. Arthritis Rheum 2003;49:314–20
   PubMed Web of Science ®Google Scholar
• Worrel LM, Krahn LE, Sletten CD, Pond GR. Treating fibromyalgia with a brief interdisciplinary program: initial outcomes and predictors of response. Mayo Clin Proc 2001;76:384–90
   PubMed Web of Science ®Google Scholar
• Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003;52:238–45
   PubMed Web of Science ®Google Scholar
• Johanek LM, Simone DA. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain 2004;109:432–42
   PubMed Web of Science ®Google Scholar
• Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 2000;57:288–95
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Stander S, Seeliger S, Ansel JC, et al. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003;139:1479–88
   PubMedGoogle Scholar
• Schmelz M, Zeck S, Raithel M, Rukwied R. Mast cell tryptase in dermal neurogenic inflammation. Clin Exp Allergy 1999;29: 652–9
   PubMedGoogle Scholar
• Khasabova IA, Harding-Rose C, Simone DA, Seybold VS. Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons. J Neurosci 2004;24:1744–53
   PubMed Web of Science ®Google Scholar
• Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004;74:1317–24
   PubMed Web of Science ®Google Scholar
• Koppert W, Angst M, Alsheimer M, Sittl R, et al. Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. Pain 2003;106:91–9
   Google Scholar
• Ibrahim MM, Porreca F, Lai J, Albrecht PJ, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 2005;102: 3093–8
   Google Scholar
• Buggy DJ, Toogood L, Maric S, Sharpe P, et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003;106: 169–72
   Google Scholar
• Johanek LM, Heitmiller DR, Turner M, Nader N, et al. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 2001;93:303–15
   Google Scholar
• Bennett RM. The rational management of fibromyalgia patients. Rheum Dis Clin North Am 2002;28:181–99
   PubMed Web of Science ®Google Scholar
• Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003;48:1420–9
   PubMed Web of Science ®Google Scholar
• Dirks J, Petersen KL, Rowbotham MC, Dahl JB. Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Anesthesiology 2002;97:102–7
   PubMed Web of Science ®Google Scholar
• Russo EB. Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett 2004; 25:31–9
   PubMed Web of Science ®Google Scholar